Literature DB >> 33199324

Raynaud's phenomenon.

Ashraful Haque1, Michael Hughes2.   

Abstract

Raynaud's phenomenon (RP) is a common vasospastic condition which affects ~5% of the general population. The majority of individuals have primary RP; however, Raynaud's can also occur secondary to a broad range of underlying medical conditions and drug therapies. RP is a cardinal feature in patients with systemic sclerosis and is often the earliest symptom of the disease. Unlike primary RP, patients with secondary RP can develop persistent digital ischaemia, including ulcers and gangrene. Patients require a comprehensive clinical assessment and investigation, in particular, the detection of autoantibodies and nailfold capillaroscopic abnormalities. Non-pharmacological management is indicated in all patients. There are a wide range of available drug therapies to treat RP, including when complicated by digital ulceration, and surgical intervention is sometimes required. Future research is needed to understand the complex pathogenesis of RP and to measure the impact and severity of RP to develop optimised approaches to management. © Royal College of Physicians 2020. All rights reserved.

Entities:  

Keywords:  Raynaud's phenomenon; digital ulcers; systemic sclerosis

Year:  2020        PMID: 33199324      PMCID: PMC7687329          DOI: 10.7861/clinmed.2020-0754

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  65 in total

Review 1.  [Heredity and genetic aspects of Raynaud's disease].

Authors:  M A Pistorius; B Planchon; J J Schott; H Lemarec
Journal:  J Mal Vasc       Date:  2006-02

2.  Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease.

Authors:  Batsi Chikura; Tonia Moore; Joanne Manning; Andy Vail; Ariane L Herrick
Journal:  J Rheumatol       Date:  2010-03-01       Impact factor: 4.666

3.  Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis.

Authors:  Pia Moinzadeh; Nicolas Hunzelmann; Thomas Krieg
Journal:  J Am Acad Dermatol       Date:  2011-09       Impact factor: 11.527

Review 4.  Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors.

Authors:  Armen Yuri Gasparyan; Lilit Ayvazyan; Heather Blackmore; George D Kitas
Journal:  Rheumatol Int       Date:  2011-07-29       Impact factor: 2.631

5.  Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception.

Authors:  Michael Hughes; Amir Snapir; Jack Wilkinson; Daniel Snapir; Fredrick M Wigley; Ariane L Herrick
Journal:  Rheumatology (Oxford)       Date:  2015-03-09       Impact factor: 7.580

6.  Patterns of finger capillary abnormalities in connective tissue disease by "wide-field" microscopy.

Authors:  H R Maricq; E C LeRoy
Journal:  Arthritis Rheum       Date:  1973 Sep-Oct

7.  Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey.

Authors:  Marielle Bassel; Marie Hudson; Suzanne S Taillefer; Orit Schieir; Murray Baron; Brett D Thombs
Journal:  Rheumatology (Oxford)       Date:  2010-12-11       Impact factor: 7.580

8.  Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.

Authors:  John D Pauling; Tracy M Frech; Michael Hughes; Jessica K Gordon; Robyn T Domsic; Marina E Anderson; Francesca Ingegnoli; Neil J McHugh; Sindhu R Johnson; Marie Hudson; Francesco Boin; Voon H Ong; Marco Matucci-Cerinic; Nezam Altorok; Marina Scolnik; Mandana Nikpour; Ankoor Shah; Janet E Pope; Dinesh Khanna; Ariane L Herrick
Journal:  J Scleroderma Relat Disord       Date:  2018-05-24

9.  Association of Raynaud's phenomenon with a polymorphism in the NOS1 gene.

Authors:  Sabrina Munir; Maxim B Freidin; Susan Brain; Frances M K Williams
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

10.  Development of a UV-Stabilized Topical Formulation of Nifedipine for the Treatment of Raynaud Phenomenon and Chilblains.

Authors:  Ellen K Wasan; Jinying Zhao; Joshua Poteet; Munawar A Mohammed; Jaweria Syeda; Kevin Soulsbury; Jacqueline Cawthray; Amanda Bunyamin; Chi Zhang; Brian M Fahlman; Ed S Krol
Journal:  Pharmaceutics       Date:  2019-11-09       Impact factor: 6.321

View more
  2 in total

Review 1.  Practical management of Raynaud's phenomenon - a primer for practicing physicians.

Authors:  Ahmad Ramahi; Michael Hughes; Dinesh Khanna
Journal:  Curr Opin Rheumatol       Date:  2022-06-09       Impact factor: 4.941

Review 2.  Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies.

Authors:  Iqra Nawaz; Yashfa Nawaz; Eisha Nawaz; Muhammad Romail Manan; Adil Mahmood
Journal:  Cureus       Date:  2022-01-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.